The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Low HER2-expression to predict impaired activity of endocrine therapy in patients with estrogen-receptor (ER) positive metastatic breast cancer (MBC).
Cornelia Sparber
No relevant relationships to disclose
Anna Sophie Berghoff
No relevant relationships to disclose
Margaretha Rudas
No relevant relationships to disclose
Peter Christian Dubsky
No relevant relationships to disclose
Catharina DeVries
No relevant relationships to disclose
Christoph Minichsdorfer
No relevant relationships to disclose
Claudia Sattlberger
No relevant relationships to disclose
Robert M Mader
No relevant relationships to disclose
Zsuzsanna Bago-Horvath
No relevant relationships to disclose
Florian Fitzal
No relevant relationships to disclose
Michael Gnant
No relevant relationships to disclose
Andrea Rottenfusser
No relevant relationships to disclose
Christoph Zielinski
No relevant relationships to disclose
Matthias Preusser
No relevant relationships to disclose
Guenther G. Steger
No relevant relationships to disclose
Rupert Bartsch
No relevant relationships to disclose